Royal London Asset Management 13F: Adds $19M to HALO Stake

Royal London Asset Management has increased its stake in Halozyme Therapeutics, Inc. (NasdaqGS: HALO) by 17.4%, according to its latest 13F filing with the SEC. The fund added 239,282 shares during the reporting period, bringing its total holdings to 1,610,553 shares valued at approximately $110.4 million.

What Changed in Royal London Asset Management's Halozyme Therapeutics Position

Royal London Asset Management boosted its position in Halozyme Therapeutics by 239,282 shares, increasing its holdings from 1,371,271 shares to 1,610,553 shares. This 17.4% increase reflects a strategic decision to enhance its investment in the biotechnology company.

Other Institutional Activity in Halozyme Therapeutics

Other major institutional investors have also adjusted their positions in Halozyme Therapeutics. BlackRock, Inc. grew its holdings by 111,196 shares, ending with 13,265,053 shares worth about $857.3 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both established new positions, each holding approximately 5.27 million and 5.25 million shares valued at $340.7 million and $339.3 million, respectively. Meanwhile, State Street Corp trimmed its holdings by 183,818 shares, now owning 4,937,854 shares valued at $319.1 million. Invesco Ltd. added 364,431 shares, bringing its total to 4,012,494 shares worth $259.3 million.

Halozyme Therapeutics, Inc. Stock Down 35.6%

Shares of Halozyme Therapeutics traded near $68.55. The company has a market cap of $8.13 billion and a P/E ratio of 24.05, with a forward P/E of 6.93. The stock's beta is 0.869, indicating lower volatility compared to the market. Over the past year, the stock has ranged from $51.06 to $82.22. Its 50-day moving average is $67.86, and the 200-day moving average is $69.17. The company's financial health is supported by a current ratio of 2.76 and a quick ratio of 2.14, although it has a high debt-to-equity ratio of 991.21.

Recent Earnings

Halozyme Therapeutics reported revenue of $1.51 billion, reflecting a growth of 42.2%. The company achieved a net margin of 23.13% and a return on equity of 99.4%. Earnings per share stood at $2.85. The next earnings report is expected on August 4, 2026.

Insider Buying and Selling at Halozyme Therapeutics, Inc.

Insider trading activities have been notable at Halozyme Therapeutics. On June 12, 2026, Mark Howard Snyder, SVP and Chief Legal Officer, sold 2,715 shares at an average price of $69.50. On the same day, he also bought 5,034 shares. Earlier, on June 3, 2026, CEO Helen Torley sold 10,000 shares at $69.07 under a planned transaction, while also purchasing 10,000 shares at $12.07.

Analysts Set New Price Targets

Analysts remain optimistic about Halozyme Therapeutics. On May 12, 2026, Morgan Stanley maintained its 'buy' rating with a price target of $93. HC Wainwright & Co. also maintained a 'buy' rating with a target of $95 on April 29, 2026. Overall, the consensus recommendation for Halozyme is a 'buy', with a mean target price of $83.90 based on 10 analyst opinions.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and commercializing proprietary enzymes and devices that enhance the delivery of injectable biologics and other therapeutic molecules. The company's flagship product, Hylenex recombinant, facilitates the subcutaneous administration of drugs, improving their absorption. Halozyme collaborates with several global pharmaceutical companies, including Roche, Pfizer, and AbbVie.

Bottom Line

Royal London Asset Management's increased stake in Halozyme Therapeutics suggests confidence in the company's prospects. As a player in the biotechnology sector, Halozyme's innovative enzyme technology and strategic partnerships position it well in the market. Investors should note that 13F filings are backward-looking, reflecting positions as of the end of the reporting period.